Buchang Pharmaceutical announced that the company held a board of directors meeting on July 21, 2026 to review and pass a proposal to increase capital in the same proportion to the holding subsidiary Buchang Yingxi Trading. This time, the company and other shareholders will increase its capital by 4 million yuan in cash at the price of 1 yuan/share according to the current shareholding ratio, and the company will invest 3.6 million yuan. After the capital increase, the registered capital of Bu Chang Yingxi Trading will increase from 1 million yuan to 5 million yuan, and the shareholders' shareholding ratio will not change. The matter does not require consideration by a shareholders' meeting and does not constitute a related or major asset restructuring. There is no significant impact of this investment. It has a positive effect in the long run, but implementation may be at risk.

Buchang Pharmaceutical announced that the company held a board of directors meeting on July 21, 2026 to review and pass a proposal to increase capital in the same proportion to the holding subsidiary Buchang Yingxi Trading. This time, the company and other shareholders will increase its capital by 4 million yuan in cash at the price of 1 yuan/share according to the current shareholding ratio, and the company will invest 3.6 million yuan. After the capital increase, the registered capital of Bu Chang Yingxi Trading will increase from 1 million yuan to 5 million yuan, and the shareholders' shareholding ratio will not change. The matter does not require consideration by a shareholders' meeting and does not constitute a related or major asset restructuring. There is no significant impact of this investment. It has a positive effect in the long run, but implementation may be at risk.